Repligen Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>RE</div>
RGEN -- USA Stock  

USD 144.30  4.36  3.12%

Repligen Average Equity is quite stable at the moment as compared to the past year. The company's current value of Average Equity is estimated at 152.43 Million. Enterprise Value is projected to rise to about 950.6 M this year, although the value of Invested Capital will most likely fall to about 40.7 M. The basic goal of this thesis is to give institutional investors our perspective on Repligen for August. We will forecast Repligen value for institutional investors.
Published over a month ago
View all stories for Repligen | View All Stories
Are Repligen (NASDAQ:RGEN) institutional investors starting to hold back?
Repligen is OVERVALUED at 138.42 per share with modest projections ahead. Over 85.0% of Repligen shares are owned by institutional investors. Institutional ownership of Repligen refers to the amount of Repligen equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Repligen, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Repligen. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Repligen


How important is Repligen's Liquidity

Repligen financial leverage refers to using borrowed capital as a funding source to finance Repligen ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Repligen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Repligen's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Repligen, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Anthony Hunt of 45351 shares of Repligen subject to Rule 16b-3

Legal trades by Repligen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Repligen insider trading alert for exercise of stock option (right to buy) by Anthony Hunt, Chief Executive Officer, on 14th of September 2020. This event was filed by Repligen Corp with SEC on 2020-09-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Repligen

Repligen currently demonstrates below-verage downside deviation. It has Information Ratio of 0.04 and Jensen Alpha of 0.24. However, we do advice investors to further question Repligen expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Returns Breakdown

2.02
Return on Assets
2.62
Return on Equity
Return on Investment3.68
Return on Assets2.02
Return on Equity2.62
Return Capital0.11
Return on Sales0.14

Are Repligen technical ratios showing a collapse?

Latest kurtosis is at 0.5. Repligen currently demonstrates below-verage downside deviation. It has Information Ratio of 0.04 and Jensen Alpha of 0.24. However, we do advice investors to further question Repligen expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Final Take On Repligen

Whereas some other firms within the medical instruments & supplies industry are still a little expensive, even after the recent corrections, Repligen may offer a potential longer-term growth to institutional investors. In closing, as of the 30th of July 2020, our final 30 days buy-hold-sell advice on the company is Hold. We believe Repligen is overvalued with very small chance of bankruptcy for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Repligen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com